Equity research analysts expect ChromaDex Co. (NASDAQ:CDXC) to report earnings of ($0.11) per share for the current quarter, according to Zacks. Three analysts have made ChromaDex earnings estimates, with the lowest EPS estimate being $0.14 and the highest estimate of $0.09. ChromaDex posted earnings per share of ($0.10) in the same quarter last year, indicating a negative 10% year-over-year growth rate. The company is expected to release its next quarterly results on Wednesday, March 9.
On average, analysts expect ChromaDex to report annual earnings of ($0.43) per share for the current year, with EPS estimates ranging from ($0.46) to ($0.40 $). For the next fiscal year, analysts expect the company to report earnings of ($0.11) per share, with EPS estimates ranging from ($0.18) to ($0.03). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts who provide coverage for ChromaDex.
Separately, Zacks Investment Research upgraded ChromaDex from a “sell” rating to a “hold” rating in a Monday, January 10 report.
A number of large investors have been buying and selling stocks recently. Citigroup Inc. increased its position in ChromaDex shares by 66.8% during the third quarter. Citigroup Inc. now owns 5,339 shares of the company worth $33,000 after purchasing an additional 2,139 shares during the period. Royal Bank of Canada increased its holdings of ChromaDex shares by 70.8% in the third quarter. Royal Bank of Canada now owns 5,482 shares of the company valued at $35,000 after buying 2,273 more shares last quarter. Campbell & CO Investment Adviser LLC bought a new position in ChromaDex stock in the fourth quarter worth $38,000. ProShare Advisors LLC bought a new position in ChromaDex stock in the fourth quarter worth $38,000. Finally, BNP Paribas Arbitrage SA increased its stake in ChromaDex by 45.7% during the 4th quarter. BNP Paribas Arbitrage SA now owns 12,776 shares of the company valued at $48,000 after purchasing an additional 4,005 shares during the period. Institutional investors and hedge funds hold 40.02% of the company’s shares.
These are the Penny Stock patterns that every trader should be able to spot. Two of them were responsible for my biggest winners.
Click here to get your free copy now.
NASDAQ:CDXC shares opened at $2.71 on Friday. The company’s fifty-day moving average price is $3.25 and its two-hundred-day moving average price is $5.47. The stock has a market capitalization of $185.07 million, a PE ratio of -6.30 and a beta of 1.75. ChromaDex has a one-year low of $2.41 and a one-year high of $23.66.
ChromaDex Company Profile
Chromadex Corp. is a global bioscience company, which engages in the acquisition, development and commercialization of proprietary ingredient technologies. He is a pioneer in research on nicotinamide adenine dinucleotide (NAD+). The Company’s patent portfolio includes nicotinamide riboside (NR) and other NAD+ precursors, which are marketed as the lead ingredient Niagen.
Get a Free Copy of Zacks Research Report on ChromaDex (CDXC)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in ChromaDex right now?
Before you consider ChromaDex, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes viral…and ChromaDex wasn’t on the list.
While ChromaDex currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here